Christi A Wisniewski
Research Subjects
Research Interests
Christi A Wisniewski has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Arthur M. Mercurio
Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA
1 shared publication - Ayush Kumar
Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA
1 shared publication - Hira Lal Goel
Department of Molecular, Cell and Cancer Biology
1 shared publication - Jennifer L. Clark
Department of Pathology, University of Massachusetts Medical School, Worcester, MA, USA
1 shared publication - Kai Hu
Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, USA
1 shared publication - Lihua Julie Zhu
Department of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA
1 shared publication
Latest Publications
- Open Access
- 1 October 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (22)
Neuropilin-2–expressing breast cancer cells mitigate radiation-induced oxidative stress through nitric oxide signaling
The high rate of recurrence after radiation therapy in triple-negative breast cancer (TNBC) indicates that novel approaches and targets are needed to enhance radiosensitivity. Here, we report that neuropilin-2 ( NRP2 ), a receptor for vascular endothelial growth factor ( VEGF ) that is enriched on subpopulations of TNBC cells with stem cell properties, is an effective therapeutic target for sensitizing TNBC to radiotherapy. Specifically, VEGF/NRP2 signaling induces nitric oxide synthase 2 ( NOS2 ) transcription by a mechanism dependent on Gli1. NRP2-expressing tumor cells serve as a hub to produce nitric oxide (NO), an autocrine and paracrine signaling metabolite, which promotes cysteine-nitrosylation of Kelch-like ECH-associated protein 1 ( KEAP1 ) and, consequently, nuclear factor erythroid 2-related factor 2–mediated ( NFE2L2 -mediated) transcription of antioxidant response genes. Inhibiting VEGF binding to NRP2, using a humanized mAb, results in NFE2L2 degradation via KEAP1, rendering cell lines and organoids vulnerable to irradiation. Importantly, treatment of patient-derived xenografts with the NRP2 mAb and radiation resulted in significant tumor necrosis and regression compared with radiation alone. Together, these findings reveal a targetable mechanism of radioresistance, and they support the use of NRP2 mAb as an effective radiosensitizer in TNBC.
- 1 October 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (22)
Open AccessNeuropilin-2–expressing breast cancer cells mitigate radiation-induced oxidative stress through nitric oxide signaling
The high rate of recurrence after radiation therapy in triple-negative breast cancer (TNBC) indicates that novel approaches and targets are needed to enhance radiosensitivity. Here, we report that neuropilin-2 ( NRP2 ), a receptor for vascular endothelial growth factor ( VEGF ) that is enriched on subpopulations of TNBC cells with stem cell properties, is an effective therapeutic target for sensitizing TNBC to radiotherapy. Specifically, VEGF/NRP2 signaling induces nitric oxide synthase 2 ( NOS2 ) transcription by a mechanism dependent on Gli1. NRP2-expressing tumor cells serve as a hub to produce nitric oxide (NO), an autocrine and paracrine signaling metabolite, which promotes cysteine-nitrosylation of Kelch-like ECH-associated protein 1 ( KEAP1 ) and, consequently, nuclear factor erythroid 2-related factor 2–mediated ( NFE2L2 -mediated) transcription of antioxidant response genes. Inhibiting VEGF binding to NRP2, using a humanized mAb, results in NFE2L2 degradation via KEAP1, rendering cell lines and organoids vulnerable to irradiation. Importantly, treatment of patient-derived xenografts with the NRP2 mAb and radiation resulted in significant tumor necrosis and regression compared with radiation alone. Together, these findings reveal a targetable mechanism of radioresistance, and they support the use of NRP2 mAb as an effective radiosensitizer in TNBC.